

H Robert Superko

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4091486/h-robert-superko-publications-by-year.pdf>
Version: 2024-04-11

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

82 papers	4,498 citations	32 h-index	66 g-index
88 ext. papers	4,887 ext. citations	6.5 avg, IF	5 L-index

#	Paper	IF	Citations
82	The Role of Genetics in Preventive Cardiology: Utility of Clinically Available Genetic Tests. <i>Contemporary Cardiology</i> , 2021 , 335-364	0.1	
81	The importance of cholesterol follow-up testing under current statin treatment guidelines. <i>Preventive Medicine</i> , 2019 , 121, 150-157	4.3	3
80	Effects of weight change on apolipoprotein B-containing emerging atherosclerotic cardiovascular disease (ASCVD) risk factors. <i>Lipids in Health and Disease</i> , 2019 , 18, 154	4.4	7
79	Trends in low-density lipoprotein-cholesterol blood values between 2012 and 2017 suggest sluggish adoption of the recent 2013 treatment guidelines. <i>Clinical Cardiology</i> , 2019 , 42, 101-110	3.3	10
78	Effects of weight change on HDL-cholesterol and its subfractions in over 28,000 men and women. <i>Journal of Clinical Lipidology</i> , 2019 , 13, 308-316	4.9	4
77	Hepatic Steatosis and Insulin Resistance, But Not Steatohepatitis, Promote Atherogenic Dyslipidemia in NAFLD. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016 , 101, 644-52	5.6	95
76	Genetic and immunologic susceptibility to statin-related myopathy. <i>Atherosclerosis</i> , 2015 , 240, 260-71	3.1	26
75	Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial. <i>Circulation</i> , 2015 , 132, 2220-9	16.7	73
74	Genetics and personalized medicine--a role in statin therapy?. <i>Current Atherosclerosis Reports</i> , 2014 , 16, 384	6	13
73	Omega-3 Fatty Acid Blood Levels Clinical Significance Update. <i>Current Cardiovascular Risk Reports</i> , 2014 , 8, 407	0.9	40
72	Providing patients with pharmacogenetic test results affects adherence to statin therapy: results of the Additional KIF6 Risk Offers Better Adherence to Statins (AKROBATS) trial. <i>Pharmacogenomics Journal</i> , 2014 , 14, 272-80	3.5	36
71	Omega-3 fatty acid blood levels: clinical significance and controversy. <i>Circulation</i> , 2013 , 128, 2154-61	16.7	76
70	Blood cholesterol trends 2001-2011 in the United States: analysis of 105 million patient records. <i>PLoS ONE</i> , 2013 , 8, e63416	3.7	16
69	High-density lipoprotein subclasses and their relationship to cardiovascular disease. <i>Journal of Clinical Lipidology</i> , 2012 , 6, 496-523	4.9	92
68	Statins personalized. <i>Medical Clinics of North America</i> , 2012 , 96, 123-39	7	33
67	Firefighters, heart disease, and aspects of insulin resistance: the FEMA Firefighter Heart Disease Prevention study. <i>Journal of Occupational and Environmental Medicine</i> , 2011 , 53, 758-64	2	16
66	Genetic testing for early detection of individuals at risk of coronary heart disease and monitoring response to therapy: challenges and promises. <i>Current Atherosclerosis Reports</i> , 2011 , 13, 396-404	6	11

65 The Statin Response Gene: KIF6 **2011**, 175-198

64 Letter by Superko and King regarding article, "Lipid Treatment Assessment Project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals". *Circulation*, **2010**, 121, e233 16.7 2

63 Statins in acute coronary syndromes and genetic insight. *Journal of the American College of Cardiology*, **2010**, 55, 1281-1282 15.1 1

62 Combination of niacin extended-release and simvastatin results in a less atherogenic lipid profile than atorvastatin monotherapy. *Vascular Health and Risk Management*, **2010**, 6, 1065-75 4.4 10

61 Family coronary heart disease: a call to action. *Clinical Cardiology*, **2010**, 33, E1-6 3.3 5

60 KIF6 polymorphism as a predictor of risk of coronary events and of clinical event reduction by statin therapy. *American Journal of Cardiology*, **2010**, 106, 994-8 3 43

59 Advanced lipoprotein testing and subfractionation are clinically useful. *Circulation*, **2009**, 119, 2383-95 16.7 53

58 Effect of combination nicotinic acid and gemfibrozil treatment on intermediate density lipoprotein, and subclasses of low density lipoprotein and high density lipoprotein in patients with combined hyperlipidemia. *American Journal of Cardiology*, **2009**, 103, 387-92 3 14

57 Influence of symptomatic status on the prevalence of obstructive coronary artery disease in patients with zero calcium score. *Atherosclerosis*, **2009**, 203, 533-7 3.1 67

56 Lipid management to reduce cardiovascular risk: a new strategy is required. *Circulation*, **2008**, 117, 560-8; discussion 568 16.7 79

55 Is it LDL particle size or number that correlates with risk for cardiovascular disease?. *Current Atherosclerosis Reports*, **2008**, 10, 377-85 6 60

54 Gemfibrozil reduces small low-density lipoprotein more in normolipemic subjects classified as low-density lipoprotein pattern B compared with pattern A. *American Journal of Cardiology*, **2005**, 96, 1266-72 3 35

53 Differential effect of two nicotinic acid preparations on low-density lipoprotein subclass distribution in patients classified as low-density lipoprotein pattern A, B, or I. *American Journal of Cardiology*, **2004**, 94, 588-94 3 26

52 Hypercholesterolemia and Dyslipidemia: Issues for the Clinician. *Current Treatment Options in Cardiovascular Medicine*, **2003**, 5, 35-50 2.1 5

51 Smallest LDL particles are most strongly related to coronary disease progression in men. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2003**, 23, 314-21 9.4 106

50 Prediction of native coronary artery disease progression following PTCA or CABG in the Emory Angioplasty Versus Surgery Trial. *Medical Science Monitor*, **2003**, 9, CR48-54 3.2 9

49 Small LDL and its clinical importance as a new CAD risk factor: a female case study. *Progress in Cardiovascular Nursing*, **2002**, 17, 167-73 13

48 Relation of coronary artery calcium identified by electron beam tomography to serum lipoprotein levels and implications for treatment. *American Journal of Cardiology*, **2001**, 87, 406-12 3 44

47	Metabolic disorders contribute to subclinical coronary atherosclerosis in patients with coronary calcification. <i>American Journal of Cardiology</i> , 2001 , 88, 260-4	3	24
46	Lipoprotein subclasses and atherosclerosis. <i>Frontiers in Bioscience - Landmark</i> , 2001 , 6, d355-365	2.8	14
45	Small, dense, low-density lipoprotein and atherosclerosis. <i>Current Atherosclerosis Reports</i> , 2000 , 2, 226-36		16
44	Garlic powder, effect on plasma lipids, postprandial lipemia, low-density lipoprotein particle size, high-density lipoprotein subclass distribution and lipoprotein(a). <i>Journal of the American College of Cardiology</i> , 2000 , 35, 321-6	15.1	83
43	Small, dense low-density lipoprotein subclass pattern B: issues for the clinician. <i>Current Atherosclerosis Reports</i> , 1999 , 1, 50-7	6	9
42	Long-term blood cholesterol-lowering effects of a dietary fiber supplement. <i>American Journal of Preventive Medicine</i> , 1999 , 17, 18-23	6.1	57
41	Inclusion of lipoprotein subfractions among efficacy parameters. <i>American Journal of Cardiology</i> , 1998 , 81, 52F-55F	3	3
40	Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. <i>American Journal of Cardiology</i> , 1998 , 82, 737-43	3	182
39	Did grandma give you heart disease? The new battle against coronary artery disease. <i>American Journal of Cardiology</i> , 1998 , 82, 34Q-46Q	3	42
38	Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. <i>Metabolism: Clinical and Experimental</i> , 1998 , 47, 1097-104	12.7	200
37	Elevated high-density lipoprotein cholesterol, not protective in the presence of homocysteinemia. <i>American Journal of Cardiology</i> , 1997 , 79, 705-6	3	6
36	Effect of fluvastatin on low-density lipoprotein peak particle diameter. <i>American Journal of Cardiology</i> , 1997 , 80, 78-81	3	59
35	27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 4. Efficacy of risk factor management. <i>Journal of the American College of Cardiology</i> , 1996 , 27, 991-1006	15.1	43
34	What can we learn about dense low density lipoprotein and lipoprotein particles from clinical trials?. <i>Current Opinion in Lipidology</i> , 1996 , 7, 363-8	4.4	32
33	Cost-effective treatment of coronary artery disease--the new imperative. <i>Clinical Cardiology</i> , 1996 , 19, 650-5	3.3	7
32	Lipid disorders contributing to coronary heart disease: an update. <i>Current Problems in Cardiology</i> , 1996 , 21, 736-80	17.1	4
31	Exercise and Lipoprotein Metabolism. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 1995 , 2, 310-315		1
30	Sophisticated primary and secondary atherosclerosis prevention is cost effective. <i>Canadian Journal of Cardiology</i> , 1995 , 11 Suppl C, 35C-40C	3.8	

29	New aspects in lipidology and atherosclerosis. <i>Canadian Journal of Cardiology</i> , 1995 , 11 Suppl C, 4C-8C	3.8	
28	Coronary artery disease regression. Convincing evidence for the benefit of aggressive lipoprotein management. <i>Circulation</i> , 1994 , 90, 1056-69	16.7	142
27	Effects of cessation of caffeinated-coffee consumption on ambulatory and resting blood pressure in men. <i>American Journal of Cardiology</i> , 1994 , 73, 780-4	3	23
26	Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease. The Stanford Coronary Risk Intervention Project (SCRIP). <i>Circulation</i> , 1994 , 89, 975-90	16.7	700
25	A case-management system for coronary risk factor modification after acute myocardial infarction. <i>Annals of Internal Medicine</i> , 1994 , 120, 721-9	8	546
24	Association of lipoprotein subclass distribution with use of selective and non-selective beta-blocker medications in patients with coronary heart disease. <i>Atherosclerosis</i> , 1993 , 101, 1-8	3.1	31
23	Differential effects of nicotinic acid in subjects with different LDL subclass patterns. <i>Atherosclerosis</i> , 1992 , 95, 69-76	3.1	128
22	Effects of acute and chronic alcohol consumption on postprandial lipemia in healthy normotriglyceridemic men. <i>American Journal of Cardiology</i> , 1992 , 69, 701-4	3	12
21	Effectiveness of low-dose colestipol therapy in patients with moderate hypercholesterolemia. <i>American Journal of Cardiology</i> , 1992 , 70, 135-40	3	32
20	Caffeinated and decaffeinated coffee effects on plasma lipoprotein cholesterol, apolipoproteins, and lipase activity: a controlled, randomized trial. <i>American Journal of Clinical Nutrition</i> , 1991 , 54, 599-605	7	49
19	Prevention and regression of atherosclerosis with drug therapy. <i>Clinical Cardiology</i> , 1991 , 14, 140-7	3.3	3
18	The effect of apolipoprotein E isoform difference on postprandial lipoprotein in patients matched for triglycerides, LDL-cholesterol, and HDL-cholesterol. <i>Artery</i> , 1991 , 18, 315-25		14
17	Exercise training, serum lipids, and lipoprotein particles: is there a change threshold?. <i>Medicine and Science in Sports and Exercise</i> , 1991 , 23, 677-85	1.2	15
16	Lipoprotein and hepatic lipase activity and high-density lipoprotein subclasses after cardiac transplantation. <i>American Journal of Cardiology</i> , 1990 , 66, 1131-4	3	36
15	Drug therapy and the prevention of atherosclerosis in humans. <i>American Journal of Cardiology</i> , 1989 , 64, 31G-38G	3	19
14	Effect of alpha- and selective beta-blockade for hypertension control on plasma lipoproteins, apoproteins, lipoprotein subclasses, and postprandial lipemia. <i>American Journal of Medicine</i> , 1989 , 86, 26-31	2.4	21
13	A review of combined hyperlipidaemia and its treatment with fenofibrate. <i>Journal of International Medical Research</i> , 1989 , 17, 99-112	1.4	4
12	Effects of solid and liquid guar gum on plasma cholesterol and triglyceride concentrations in moderate hypercholesterolemia. <i>American Journal of Cardiology</i> , 1988 , 62, 51-5	3	59

11	Blood cholesterol treatment attitudes of community physicians: a major problem. <i>American Heart Journal</i> , 1988 , 116, 849-55	4.9	31
10	Changes in plasma lipids and lipoproteins in overweight men during weight loss through dieting as compared with exercise. <i>New England Journal of Medicine</i> , 1988 , 319, 1173-9	59.2	551
9	The Role of Diet, Exercise, and Medication in Blood Lipid Management of Cardiac Patients. <i>Physician and Sportsmedicine</i> , 1988 , 16, 64-81	2.4	1
8	The Role of Exercise Training in the Therapy of Hyperlipoproteinemia. <i>Cardiology Clinics</i> , 1987 , 5, 285-310	10.5	15
7	High-Density Lipoprotein Cholesterol Measurements. <i>JAMA - Journal of the American Medical Association</i> , 1986 , 256, 2714	27.4	10
6	High-density lipoprotein cholesterol measurements. A help or hindrance in practical clinical medicine?. <i>JAMA - Journal of the American Medical Association</i> , 1986 , 256, 2714-7	27.4	5
5	High-density lipoprotein cholesterol measurements. A help or hindrance in practical clinical medicine?. <i>JAMA - Journal of the American Medical Association</i> , 1986 , 256, 2714-2717	27.4	16
4	Modification of plasma cholesterol through exercise. Rationale and recommendations. <i>Postgraduate Medicine</i> , 1985 , 78, 64-7, 70, 72-5	3.7	8
3	Coronary heart disease and risk factor modification. Is there a threshold?. <i>American Journal of Medicine</i> , 1985 , 78, 826-38	2.4	15
2	Effects of ozone inhalation during exercise in selected patients with heart disease. <i>American Journal of Medicine</i> , 1984 , 77, 463-70	2.4	12
1	EFFECTS OF A MANDATORY JOB PERFORMANCE TEST AND VOLUNTARY REMEDIATION PROGRAM ON LAW ENFORCEMENT PERSONNEL. <i>Medicine and Science in Sports and Exercise</i> , 1983 , 15, 149	1.2	2